The FDA cleared Jemperli, known generically as dostarlimab, as an immunotherapy treatment for adults diagnosed with stage II and III microsatellite instability-high or mismatch repair deficient locally advanced rectal cancer. While the drug is now a clinical reality for patients, the commercial and research heavy lifting remains with GSK unit Tesaro, which holds the license for the therapy's development and manufacturing.

AnaptysBio retains its role in managing the financial collaborations surrounding the drug, alongside another pipeline project currently under development with Vanda. The market reaction underscores investor confidence in the company’s ability to monetize its discovery portfolio through these long-standing licensing agreements.